LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 5 of 15: Mean cell count and mean growth rate across biological replicate 2. - Dataset (ID:20241)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Timepoint | Timepoint Unit | Mean Total Cell Count Before Treatment | Mean Total Cell Count After Treatment | Mean Total Control Cell Count | Mean Relative Cell Count | Mean Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Selumetinib | 0.37 | uM | LJP6 | 72 | hr | 2543 | 5549 | 5578 | 0.9947 | 0.9903 |
| SK-BR-3 | Sirolimus | 0.37 | uM | LJP6 | 72 | hr | 2543 | 3469 | 5578 | 0.6219 | 0.3050 |
| SK-BR-3 | Sorafenib | 0.37 | uM | LJP6 | 72 | hr | 2543 | 5574 | 5578 | 0.9992 | 0.9985 |
| SK-BR-3 | SU11274 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 6036 | 5578 | 1.0821 | 1.1509 |
| SK-BR-3 | Fedratinib | 0.37 | uM | LJP5 | 72 | hr | 2543 | 5527 | 5578 | 0.9908 | 0.9831 |
| SK-BR-3 | TGX221 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 5423 | 5578 | 0.9721 | 0.9487 |
| SK-BR-3 | Torin1 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 1917 | 5578 | 0.3437 | -0.2063 |
| SK-BR-3 | Torin2 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 1710 | 5578 | 0.3066 | -0.2744 |
| SK-BR-3 | Tozasertib | 0.37 | uM | LJP5 | 72 | hr | 2543 | 1987 | 5578 | 0.3563 | -0.1831 |
| SK-BR-3 | Trametinib | 0.37 | uM | LJP5 | 72 | hr | 2543 | 4010 | 5578 | 0.7189 | 0.4833 |
| SK-BR-3 | TWS119 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 6082 | 5578 | 1.0902 | 1.1658 |
| SK-BR-3 | Vemurafenib | 0.37 | uM | LJP5 | 72 | hr | 2543 | 5948 | 5578 | 1.0662 | 1.1217 |
| SK-BR-3 | Withaferin A | 0.37 | uM | LJP5 | 72 | hr | 2543 | 3576 | 5578 | 0.6410 | 0.3402 |
| SK-BR-3 | Withaferin A | 0.37 | uM | LJP6 | 72 | hr | 2543 | 2923 | 5578 | 0.5240 | 0.1252 |
| SK-BR-3 | WYE-125132 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 2034 | 5578 | 0.3647 | -0.1676 |
| SK-BR-3 | WZ3105 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 1190 | 5578 | 0.2134 | -0.4457 |
| SK-BR-3 | XMD11-50 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 4028 | 5578 | 0.7222 | 0.4893 |
| SK-BR-3 | Y39983 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 4396 | 5578 | 0.7881 | 0.6105 |
| SK-BR-3 | YM 201636 | 0.37 | uM | LJP5 | 72 | hr | 2543 | 5792 | 5578 | 1.0383 | 1.0704 |
| SK-BR-3 | ZSTK474 | 0.37 | uM | LJP6 | 72 | hr | 2543 | 2667 | 5578 | 0.4781 | 0.0408 |
| SK-BR-3 | Afatinib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1745 | 5578 | 0.3129 | -0.2629 |
| SK-BR-3 | Sigma A6730 | 1.11 | uM | LJP5 | 72 | hr | 2543 | 4238 | 5578 | 0.7598 | 0.5585 |
| SK-BR-3 | Alvocidib | 1.11 | uM | LJP6 | 72 | hr | 2543 | 911 | 5578 | 0.1633 | -0.5378 |
| SK-BR-3 | AT-7519 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1298 | 5578 | 0.2327 | -0.4102 |
| SK-BR-3 | AZD 5438 | 1.11 | uM | LJP6 | 72 | hr | 2543 | 1809 | 5578 | 0.3243 | -0.2419 |